![]() |
|
|
Vol. 289, Issue 2, 847-852, May 1999
Division of Molecular Toxicology, Institute of Environmental
Medicine, Karolinska Institutet, Stockholm, Sweden
Chlomethiazole (CMZ) is a sedative and anticonvulsant drug that has
been shown to be an efficient transcriptional inhibitor of expression
of rat hepatic ethanol-inducible cytochrome P-450 2E1 (CYP2E1). Recent
results have shown that human CYP2E1 expression in vivo is almost
completely inhibited in control subjects and in alcoholic patients
treated with CMZ. In the present investigation, we evaluated the mode
of action of CMZ on CYP2E1 expression in Fao rat hepatoma cells.
Transcriptional activity of the CYP2E1 gene was
monitored using reverse transcription-polymerase chain reaction-based
quantification of CYP2E1 heterologous nuclear RNA (hnRNA) against a mimic DNA standard, mRNA was detected
by Northern blotting, enzyme protein was detected by Western blotting,
and CYP2E1-dependent catalytic activity was detected by assay of
chlorzoxazone-6-hydroxylation. Six hours after CMZ treatment, the
levels of both CYP2E1 protein and catalytic activity were concomitantly
reduced at an IC50 value of about 5 µM. Ethanol treatment
of the cells caused a 2-fold induction of CYP2E1 protein levels, which
was inhibited by CMZ. Change of medium unexpectedly caused an increase
in CYP2E1 gene transcription 4 h later, as
monitored by quantitative determination of CYP2E1 hnRNA.
However, CMZ failed to influence the expression of CYP2E1
hnRNA or mRNA both constitutively and after medium
change, indicating no effect on gene transcription or mRNA
synthesis/stability. Cycloheximide treatment of the cells did not
abolish the inhibitory action of CMZ, further indicating an action at
the post-translational level; in addition, CMZ inhibited CYP2E1
expression in V79 cells with stably expressed CYP2E1 under the control
of the SV40 promoter. The data indicate that the CYP2E1
gene is transcriptionally activated in response to medium change and
that CMZ, apart from a transcriptional inhibitor of CYP2E1 expression,
acts in addition as an efficient high-affinity post-translational
inhibitor of CYP2E1, probably due to an allosteric destabilization of
the enzyme. This indicates a very rapid and effective CMZ-mediated
inhibition of CYP2E1 in vivo.
This article has been cited by other articles:
![]() |
V. Tamasi, E. Hazai, M. Porsmyr-Palmertz, M. Ingelman-Sundberg, L. Vereczkey, and K. Monostory GYKI-47261, A NEW AMPA [2-AMINO-3-(3-HYDROXYMETHYLISOXAZOLE-4-YL)PROPIONIC ACID] ANTAGONIST, IS A CYP2E1 INDUCER Drug Metab. Dispos., November 1, 2003; 31(11): 1310 - 1314. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hakkola, Y. Hu, and M. Ingelman-Sundberg Mechanisms of Down-Regulation of CYP2E1 Expression by Inflammatory Cytokines in Rat Hepatoma Cells J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1048 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Q. Gouillon, D. Lucas, J. Li, A. L. Hagbjork, B. A. French, P. Fu, C. Fang, M. Ingelman-Sundberg, T. M. Donohue Jr., and S. W. French Inhibition of Ethanol-Induced Liver Disease in the Intragastric Feeding Rat Model by Chlormethiazole Experimental Biology and Medicine, September 1, 2000; 224(4): 302 - 308. [Abstract] [Full Text] |
||||